Skip to main content
Download PDF
Download ePub

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study

Cardiovascular Diabetology volume 22, Article number: 278 (2023) Cite this article

Abstract

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra beneficial metabolic effects on circulating metabolites beyond glucose control, which might play a role in reducing the risk of AF. Hence, our study aimed to investigate the effect of circulating metabolites mediating SGLT2 inhibition in AF by Mendelian randomization (MR).

Methods

A two-sample and two-step MR study was conducted to evaluate the association of SGLT2 inhibition with AF and the mediation effects of circulating metabolites linking SGLT2 inhibition with AF. Genetic instruments for SGLT2 inhibition were identified as genetic variants, which were both associated with the expression of SLC5A2 gene and glycated hemoglobin level (HbA1c). Positive control analysis on type 2 diabetes mellitus (T2DM) was conducted to validate the selection of genetic instruments.

Results

Genetically predicted SGLT2 inhibition (per 1 SD decrement in HbA1c) was associated with reduced risk of T2DM (odds ratio [OR] = 0.63 [95% CI 0.45, 0.88], P = 0.006) and AF (0.51 [0.27, 0.97], P = 0.039). Among 168 circulating metabolites, two metabolites were both associated with SGLT2 inhibition and AF. The effect of SGLT2 inhibition on AF through the total concentration of lipoprotein particles (0.88 [0.81, 0.96], P = 0.004) and the concentration of HDL particles (0.89 [0.82, 0.97], P = 0.005), with a mediated proportion of 8.03% (95% CI [1.20%, 14.34%], P = 0.010) and 7.59% ([1.09%, 13.34%], P = 0.011) of the total effect, respectively.

Conclusions

This study supported the association of SGLT2 inhibition with a reduced risk of AF. The total concentration of lipoprotein particles and particularly the concentration of HDL particles might mediate this association. Further mechanistic and clinical studies research are needed to understand the mediation effects of circulating metabolites especially blood lipids in the association between SGLT2 inhibition and AF.

Introduction

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of oral antidiabetic drugs, which reduce serum glucose concentration by inhibiting the reabsorption of glucose in proximal tubules and promoting urinary glucose excretion. [1] Compelling evidence has shown their benefit in improving cardiovascular, heart failure, and renal outcomes. [2,3,4,5] In addition, emerging evidence suggested their potential in decreasing the risk of atrial fibrillation (AF), but the results are controversial and the underlying metabolic mechanism remains unclear. [6,7,8,9].

SGLT2 inhibitors were believed to have extra beneficial metabolic effects beyond glycemic control, [10, 11] which might play an important role in improving cardiovascular and renal outcomes. Previous studies have demonstrated that SGLT2 inhibitors have remarkable effects on circulating metabolites, especially amino acids, ketone bodies, and lipids. [12,13,14] However, the associations between SGLT2 inhibition and circulating metabolites remain unclear, particularly for blood lipids. Some evidence implied that SGLT2 inhibition increased the total cholesterol, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol levels, [15, 16] whereas others failed to observe a significant change in the serum lipid profile. [17, 18] The discrepancy in these studies might be partially attributed to the limited sample size and the presence of residual confounding.

Mendelian randomization (MR) is a powerful approach that uses genetic variants associated with exposure as instruments to examine the potential causal association between exposure and outcome. MR is less likely to be affected by confounding or reverse causality, [19] as it mimics the randomized controlled trials by randomly assigning genetic variants at the time of conception. [20].

Increasing evidence suggested a correlation between metabolism disorders and the occurrence of AF. [21, 22] In a recent study that comprehensively investigated metabolomic characterization of atrial fibrillation, [23] Lu et al. found that circulating metabolites including amino acids and phospholipids might serve as biomarkers for AF onset and progression. For blood lipids, a systematic review and meta-analysis of large cohort studies found an inverse relationship between total cholesterol, LDL-cholesterol, and HDL-cholesterol levels and AF risk. [24] These findings suggested the potential role of circulating metabolites in the pathogenies of AF.

Therefore, we hypothesized that circulating metabolites might mediate the effect of SGLT2 inhibition on AF. In the present study, we first conducted a two-sample MR to examine the association between SGLT2 inhibition and AF. Second, we performed a two-step MR study to establish the potential metabolic pathway from SGLT2 inhibition to AF through circulating metabolites, particularly blood lipids. We investigated the possible causal effect of SGLT2 inhibition on circulating metabolites, which would provide insights into the metabolic mechanism linking the effect of SGLT2 inhibition with AF.

Methods

Study design

The current study was conducted using a two-sample MR design (Fig. 1). To ensure the validity of potential causal effects, MR analyses needed to fulfill three core assumptions: [19] (1) genetic variants are robustly associated with the exposure (relevance), (2) genetic variants are independent of confounders (exchangeability), (3) genetic variants influence the outcome only through the exposure (exclusion restriction). This study was reported following the Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization (STROBE-MR) guidelines. [25].

Fig. 1
figure 1

Overview of the study design. (a) The flowchart of evaluating the effects of circulating metabolites in mediating the effect of SGLT2 inhibition on atrial fibrillation. (b) The framework of the two-step MR. (c) The flow diagram of conducting the two-step MR step by step, which involved the selection of circulating metabolites HbA1c, glycated hemoglobin; MVMR, multivariable Mendelian randomization; SNP, single nucleotide polymorphism; UVMR, univariable Mendelian randomization

Full size image

Genetic instruments for SGLT2 inhibition

The identification of genetic variants for SGLT2 inhibition followed four steps (Fig. 1a). First, we used publicly available data from the Genotype-Tissue Expression (GTEx) [26] and eQTLGen Consortium [27] to select genetic variants, which were associated with mRNA expression level of the SLC5A2 (gene of SGLT2). Second, we estimated the associations of each SLC5A2 variant with glycated hemoglobin (HbA1c) level, an indicator of glucose-lowering effect, and selected variants that are significantly associated with HbA1c (P < 1 × 10− 4). The genome-wide association study (GWAS) data of HbA1c was from 344,182 unrelated individuals of European ancestry without diabetes mellitus in the UK Biobank (Supplementary Table 1). Third, colocalization analysis was performed to confirm that SLC5A2 and HbA1c share the same causal variant. [28] Evidence for colocalization was defined as a posterior probability > 70% for a shared causal variant. [29] Finally, we clumped those genetic variants to a linkage disequilibrium (LD) of r2 < 0.8 within 250 kb using the 1,000 Genomes European reference panel.

Genetic instruments for circulating metabolites

We systematically searched 249 nuclear magnetic resonance circulating metabolites from 121,000 European ancestry participants generated by Nightingale Health. [30] These metabolic biomarker data comprises 168 biomarker absolute concentrations and 81 biomarker ratios, mainly covering lipids and lipoprotein particles sub-fractions (81%) but also amino acids, cholesterol, esterified cholesterol, free cholesterol, cholines, compounds, fatty acids, glycolysis, ketone bodies, phospholipids, lipoprotein particles size, apolipoproteins, and triglycerides. The absolute concentrations of 168 biomarkers were included for MR analysis. The full GWAS summary statistics of the 168 biomarkers were publicly available through the IEU Open-GWAS Project database with GWAS identifier ‘met-d’ (Supplementary Table 1). [31] We restricted the analyses to genetic variants of each biomarker that were at a genome-wide significant (P < 5 × 10− 8) and were independent of each other (LD r2 < 0.01 within 10,000 kb).

Study outcomes

We obtained publicly available GWAS summary data for AF from Atrial Fibrillation Genetics (AFGen) Consortium (15,979 cases and 102,776 controls, European ancestry) (Supplementary Table 1). [32] The ascertainment of AF was based on an electrocardiograph recording or outpatient diagnosis. To validate our selection of instruments for SGLT2 inhibition, positive control analysis was performed with type 2 diabetes mellitus (T2DM). The summary data for T2DM were from Diabetes Genetics Replication And Meta-analysis (DIAGRAM) consortium, which accumulated association summary statistics from 122 GWAS in 180,834 T2DM cases and 1,159,055 controls across five ancestry groups. We extracted European ancestry-specific GWAS data (80,154 cases and 853,816 controls) for this study. [33].

Statistical analyses

MR analysis to estimate the effects of SGLT2 inhibition on AF and T2DM

We applied two-sample univariable MR (UVMR) to estimate the effect of SGLT2 inhibition on AF and T2DM. Before MR analysis, we used Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) [34] and radial MR [35] to detect and correct possible horizontal pleiotropy and heterogeneity by removing outlying genetic variants. The inverse variant weight (IVW) method was used as the main analysis, which can provide the most precise and powerful estimates when all genetic variants are valid instruments. [36, 37].

Mediation MR analysis linking SGLT2 inhibition with AF via circulating metabolites

Two-step MR was conducted to estimate the mediation effect of circulating metabolites on the association between SGLT2 inhibition and AF (Fig. 1b and c). First, we estimated the effect of SGLT2 inhibition on 168 circulating metabolites (𝞫1) using UVMR. Second, we evaluated the effect of those metabolites that showed statistically significant associations with SGLT2 inhibition on AF using UVMR. Then, we further screened the metabolites that demonstrated significant associations with AF and performed multivariable MR (MVMR) to evaluate the effect of each metabolite on AF after adjusting for the genetic effect of SGLT2 inhibition (𝞫2). The mediation proportion of each metabolite in the association between SGLT2 inhibition and AF was calculated as the product of 𝞫1and 𝞫2 divided by the total effect of SGLT2 inhibition on AF. The 95% confidence intervals (CIs) of the mediation proportions were calculated through the delta method. [38].

Sensitivity analysis

In UVMR analysis assessing the effects of SGLT2 inhibition on AF and T2DM, we performed the MR-Egger, MR-PRESSO, weighted median, simple mode, and weighted mode methods as sensitivity analyses. The MR-Egger method examines whether there is directional pleiotropy based on its intercept term, where a value that differs from zero indicates that the presence of directional pleiotropy and the IVW estimate is biased. [39] In addition, the MR-PRESSO method can also determine the presence of directional pleiotropy by detecting possible outliers and recalculating estimates after removing outliers. [34] The weighted median method provides a reliable estimate if at least 50% of the instruments are valid. [40] The simple mode and weighted mode methods provide a reliable estimate when the horizontal pleiotropy in the largest cluster is zero. [41, 42] In UVMR analysis evaluating the effects of SGLT2 inhibition on metabolites and the effects of metabolites on AF, we used MR-Egger and MR-PRESSO methods to validate the robustness of the MV-IVW results. In MVMR, we performed MVMR-Egger methods to validate the robustness.

The strength of the genetic instruments was assessed by F statistics and indicates weak instruments when F statistics < 10. Cochrane’s Q statistics for IVW and the global test for MR-PRESSO were calculated to evaluate the heterogeneity between the instruments.

Role of the funding source

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

All MR analyses were conducted with the package “TwoSampleMR”, “MendelianRandomization”, “MVMR”, “MRPRESSO”, and “RadialMR” in R software (version 4.2.2). To control for multiple testing, a two-sided P value that passed the Bonferroni corrected P value was defined as statistically significant, but P value < 0.05 was considered statistically significant for the effect of SGLT2 inhibition on T2DM and AF since the outcome T2DM was not the primary outcome in the present study.

Results

Effect of SGLT2 inhibition on AF and T2DM

In total, 10 independent single nucleotide polymorphisms (SNPs) were selected as genetic instruments for SGLT2 inhibition and the F statistics for all SNPs were greater than 16 (Supplementary Table 2). In MR analysis, we found that SGLT2 inhibition was associated with reduced risk of T2DM (odds ratio [OR] = 0.63 [95% CI 0.45, 0.88], P = 0.006) and AF (0.51 [0.27, 0.97], P = 0.039), for per 1 SD lowering of HbA1c via SGLT2 inhibition (Table 1). These results were supported by the sensitivity analysis of MR-PRESSO. There was no heterogeneity between instruments for the effect of SGLT2 inhibition on T2DM and AF (Q = 7.010, P = 0.536; Q = 1.780, P = 0.994), and no horizontal pleiotropy was detected (Egger intercept = 0.026, P = 0.115; Egger intercept = 0.012, P = 0.680).

Table 1 MR estimates of the effect of SGLT2 inhibition on type 2 diabetes mellitus (T2DM) and atrial fibrillation (AF)
Full size table

Mediation MR of SGLT2 inhibition, circulating metabolites, and AF

We estimated the effect of SGLT2 inhibition on the 168 circulating metabolites and observed 20 metabolites were significantly associated with SGLT2 inhibition (Bonferroni-corrected P value threshold = 2.98 × 10− 4 [0.05/168]) (Supplementary Table 3, Fig. 2a). For compounds, we observed that SGLT2 inhibition increased the total concentration of lipoprotein particles (𝞫= 0.42 [95% CI 0.22, 0.61], P = 2.23 × 10−5). For lipoprotein particles, we found that SGLT2 inhibition increased the concentration of HDL particles especially small HDL (0.43 [0.23, 0.62], P = 1.37 × 10−5 and 0.64 [0.43, 0.84], P = 9.44 × 10−10, respectively) but decreased the concentration of very large HDL particles (-0.49 [-0.73, -0.25], P = 6.35 × 10−5).

Fig. 2
figure 2

The forest plot of showing the effects of SGLT2 inhibition on circulating metabolites and the effects of metabolites on atrial fibrillation. (a) The effects of SGLT2 inhibition on the remaining 20 circulating metabolites selected from 168 metabolites, which were significantly associated with SGLT2 inhibition (Bonferroni-corrected P value threshold = 2.98 × 10− 4 [0.05/168]). (b) The effects of the above 20 metabolites on atrial fibrillation (Bonferroni-corrected P value threshold = 0.0025 [0.05/20]) CI, confidence interval; HDL, high-density lipoprotein; OR, odds ratio

Full size image

We further estimated the effect of the 20 circulating metabolites that were significantly associated with SGLT2 inhibition on AF and found that two metabolites were significantly associated with AF (Bonferroni-corrected P value threshold = 0.0025 [0.05/20]) (Supplementary Table 4, Fig. 2b). For the total concentration of lipoprotein particles, we observed a negative association with AF (OR 0.88 [95% CI 0.81, 0.96], P = 0.002). For the concentration of HDL particles, we also observed a negative association with AF (0.88 [0.82, 0.96], P = 0.002). These results were supported by the MR-PRESSO method. There was no evidence of heterogeneity (Q = 58.332, P = 0.573; Q = 65.320, P = 0.603) and no horizontal pleiotropy (Egger intercept = -0.004, P = 0.351; Egger intercept = -0.002, P = 0.623). The genetic variants for the 20 metabolites were all strong (F statistics > 23) (Supplementary Data 1–20 are available at https://0-doi-org.brum.beds.ac.uk/10.6084/m9.figshare.23731140).

We observed an indirect effect of SGLT2 inhibition on AF through the total concentration of lipoprotein particles (OR 0.88 [95% CI 0.81, 0.96], P = 0.004) (Bonferroni-corrected P value threshold = 0.025 [0.05/2]), with a mediated proportion of 8.03% (95% CI [1.20%, 14.34%], P = 0.010) of the total effect (Table 2; Fig. 3). The indirect effect of SGLT2 inhibition on AF through the concentration of HDL particles (OR 0.89 [95% CI 0.82, 0.97], P = 0.005) had a mediated proportion of 7.59% (95% CI [1.09%, 13.34%], P = 0.011). There was no evidence of heterogeneity and no horizontal pleiotropy in these associations.

Table 2 Multivariable MR estimates of the effect of circulating metabolites on atrial fibrillation after adjusting for SGLT2 inhibition
Full size table
Fig. 3
figure 3

The potential causal evidence summarized from the MR analysis HDL, high-density lipoprotein

Full size image

Discussion

Principal findings

In the present study, we evaluated the associations between genetically predicted SGLT2 inhibition and T2DM and AF. Furthermore, we investigated the mediating role of circulating metabolites in the association between SGLT2 inhibition and AF. Our study indicated that genetic variation in SGLT2 inhibition targets was associated with a lower risk of T2DM (OR 0.63 [95% CI 0.45, 0.88], P = 0.006, per 1 SD decrement in HbA1c) and AF (0.51 [0.27, 0.97], P = 0.039). The total concentration of lipoprotein particles might mediate 8% of the effect of SGLT2 inhibition on AF, particularly with the concentration of HDL particles mediating 7.6%.

The association between SGLT2 inhibition and AF

Large clinical trials and meta-analyses have investigated the role of SGLT2 inhibition in incident AF, but the results remain controversial. In the DECLARE-TIMI 58 trial, Dapagliflozin decreased the incidence of AF by 19% (hazard ratio [HR] = 0.81 [95% CI 0.68, 0.95]) in patients with T2DM. [6] However, there was no consistent reduction in incident AF in other randomized clinical trials. [7, 43] In the CANVAS trial, canagliflozin failed to decrease the risk of AF compared with placebo (0.84 [0.64, 1.12]) in T2DM patients. [43] Meta-analyses implied either no effect [8, 44] or possible protective effects [9, 45,46,47,48,49] of SGLT2 against AF. Of note, incident AF was reported as an adverse event rather than a prespecified end point and there were relatively limited AF events in previous randomized clinical trials, which influenced the robustness of the result. [50, 51] Furthermore, previous studies typically focused on patients with diabetes, heart failure, or chronic kidney disease and the protective effect of a certain SGLT2 inhibitor. It remains unclear whether these protective effects could extend to the general population and class of SGLT2 inhibition. [52, 53] Our study provided strong evidence of the protective effect of SGLT2 inhibition on AF in the general population by using a set of robust genetic instruments of SGLT2 as the instrument variables and a large GWAS for AF. Several possible mechanisms have been proposed for the protection against AF by SGLT2 inhibitors, including the modulation of risk factors and off-target actions on cardiomyocytes. [53] The former involves glucose control, weight loss, and reduction in blood pressure. [53] The latter refers to the inhibition effect of SGLT2 inhibitors on sodium-hydrogen exchanger (NHE) activity on cardiomyocytes, which interrupts the increase in intracellular Ca2+ concentration and reduces the risk of AF. [53, 54].

The association between SGLT2 inhibition and circulating metabolites

The effects of SGLT2 inhibitors on blood lipids are conflicting in previous studies. [55, 56] A retrospective study by Calapkulu et al. showed that six months of dapagliflozin treatment in T2DM patients decreased total cholesterol, LDL-cholesterol, and triglyceride (TG) levels. [16] However, a meta-analysis of 48 randomized controlled trials demonstrated that SGLT2 inhibitors significantly increased total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and HDL-cholesterol, and decreased TG levels in patients with T2DM. [15] In addition, some studies indicated no significant change in the lipid profile following SGLT2 administration. [17, 57, 58] A clinical trial on patients with T2DM performed by Bosch et al. revealed that empagliflozin had no significant effect on total cholesterol, HDL-cholesterol, and LDL-cholesterol levels. [58] Inconsistencies in these studies might be related to small sample sizes, retrospective design, potential residual confounding, or short follow-up. [59] More importantly, several studies aimed at investigating the impact of SGLT2 inhibitors on lipoprotein subclasses showed that dapagliflozin treatment for three months did not alter concentrations of LDL-cholesterol, but with a remodeling of LDL particles. [60] Highly atherogenic small dense LDL decreased by 20% and less atherogenic large buoyant LDL-cholesterol increased by 18%. Nevertheless, another randomized trial found that empagliflozin after three months of treatment in patients with T2DM increased total cholesterol, LDL-cholesterol, LDL phospholipids, LDL apolipoprotein B and free fatty acids, but had no effect on LDL particles size. [61] These findings highlighted the importance of distinguishing lipoprotein subclass by size and lipoprotein composition in exploring the effect of SGLT2 inhibition on lipid metabolism.

In our study, we provided insights into the effect of SGLT2 inhibitors on lipid metabolism by using a set of robust genetic variants of SGLT2 as the instruments and the largest circulating metabolites GWAS to date, which mainly covered blood lipids and lipoprotein particles sub-fractions. [30] We observed that SGLT2 inhibition had a significant effect on HDL subclass metabolism. SGLT2 inhibition significantly increased concentration of HDL especially small HDL but decreased levels of very large HDL. For the subclass of lipoprotein composition, we found that SGLT2 inhibition increased cholesterol, esterified cholesterol, free cholesterol, phospholipids, and total lipids levels in small HDL, but decreased these components in very large HDL (Fig. 2a). A randomized clinical trial by Fadini also found that small HDL subfraction levels increased and large HDL subfraction levels decreased after three months of treatment with dapagliflozin, though without statistical significance. [17].

The mediation effect of circulating metabolites in the association between SGLT2 inhibition and AF

Our findings support that genetically predicted total concentration of lipoprotein particles and concentration of HDL particles were associated with AF, which were consistent with previous findings from one meta-analysis [24] and several cohort studies. [62, 63] The total concentration of lipoprotein particles and concentration of HDL particles might be involved in the association between SGLT2 inhibition and AF. Oxidative stress and chronic inflammation have been proposed to mediate the protective effect of SGLT2 inhibition on AF and previous evidence suggested HDL possesses anti-inflammatory and antioxidant properties. [52, 64, 65] Furthermore, low HDL is an important component in metabolic syndrome, which is associated with an increased risk of AF. [63, 66] Therefore, HDL might mediate this protective effect. Our study provided genetic evidence that HDL might mediate the protective effect of SGLT2 inhibition on AF. Nevertheless, it’s worth noting that the mediation association observed might not be causal and needs to be further validated through experimental studies.

Strengths and limitations

To our knowledge, this is the first study to use MR analysis to investigate the relationship between SGLT2 inhibition, circulating metabolites, and AF in the general population. Furthermore, we provided genetic evidence on the potential mechanism of SGLT2 inhibition exerting a beneficial effect on AF through the total concentration of lipoprotein particles, primarily HDL. Nevertheless, our study had several limitations. First, genetic variants mimicking SGLT2 inhibition reflect lifelong effects of SGLT2 inhibitors, and the magnitude of these effects might not accurately reflect the magnitude of short-term effects of SGLT2 inhibitors. [67] Hence, MR analysis is more helpful to examine the direction of the potential causal effect rather than quantifying its magnitude. However, the expected direction of effects can inform potential efficacy, which can be further explored in experiments and clinical trials. Second, there are overlapped samples of GWAS for SGLT2 inhibition and the circulating metabolites, the GWAS for Nightingale Health metabolites was conducted in around 24.2% of the UK Biobank. In the case of the weak instruments, sample overlap between exposure and outcome could bias the potential causal effect estimate by introducing associations between instruments and confounders. [68] However, the genetic variants for SGLT2 inhibition in this study were strongly associated with exposure indicated by high F-statistics (all > 16), which implied that our results were unlikely biased by weak instruments. Third, the lack of large public GWAS data for lipids and lipids subfractions like metabolic profiling by Nightingale Health limited further validation of our findings. [69] Finally, as this study was performed using data from individuals of European ancestry, the generalization of these results to other populations warrants further investigation.

Conclusions

In conclusion, this study supported the association between genetically predicted SGLT2 inhibition, circulating metabolites, and AF. Specifically, the total concentration of lipoprotein particles, especially HDL particle concentration, mediated the protective effect of SGLT2 inhibition on AF. These findings provided genetic evidence for the mechanisms of SGLT2 inhibition in reducing AF risk and might inform future mechanistic and clinical studies.

Data Availability

The GWAS Summary statistics used in this study were publicly accessed from the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/), the GTEx Portal (https://www.gtexportal.org/), the eQTLGen Consortium (https://eqtlgen.org/) and the DIAGRAM consortium (https://diagram-consortium.org/).

Abbreviations

AF:

atrial fibrillation

GWAS:

genome-wide association study

HbA1c:

glycated hemoglobin

HDL:

high-density lipoprotein

IVW:

inverse variant weight

LDL:

low-density lipoprotein

MR:

Mendelian randomization

MVMR:

multivariable Mendelian randomization

SGLT2:

Sodium-glucose cotransporter 2 T2DM: type 2 diabetes mellitus

UVMR:

univariable Mendelian randomization

References

  1. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of Diabetes Mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72.

    CAS  PubMed  Google Scholar 

  2. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with Diabetes and chronic Kidney Disease. N Engl J Med. 2021;384(2):129–39.

    CAS  PubMed  Google Scholar 

  3. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425–35.

    CAS  PubMed  Google Scholar 

  4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 Diabetes. N Engl J Med. 2017;377(7):644–57.

    CAS  PubMed  Google Scholar 

  5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 2019;380(4):347–57.

    CAS  PubMed  Google Scholar 

  6. Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of Dapagliflozin on Atrial Fibrillation in patients with type 2 Diabetes Mellitus: insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227–34.

    CAS  PubMed  Google Scholar 

  7. Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, et al. Effect of SGLT2 inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: results from the CREDENCE Trial and Meta-Analysis. Stroke. 2021;52(5):1545–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Ouyang X, Wang J, Chen Q, Peng L, Li S, Tang X. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with Heart Failure: a systematic review. Cardiovasc Diabetol. 2023;22(1):124.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):100.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–72.

    CAS  PubMed  Google Scholar 

  11. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: a thrifty substrate hypothesis. Diabetes Care. 2016;39(7):1108–14.

    PubMed  Google Scholar 

  12. Kappel BA, Lehrke M, Schütt K, Artati A, Adamski J, Lebherz C, et al. Effect of Empagliflozin on the metabolic signature of patients with type 2 Diabetes Mellitus and Cardiovascular Disease. Circulation. 2017;136(10):969–72.

    CAS  PubMed  Google Scholar 

  13. Katano S, Yano T, Kouzu H, Nagaoka R, Numazawa R, Yamano K, et al. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in Heart Failure patients with type 2 Diabetes receiving sodium-glucose cotransporter 2 inhibitors. Cardiovasc Diabetol. 2022;21(1):285.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2).

  15. Sánchez-García A, Simental-Mendía M, Millán-Alanís JM, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020;160:105068.

    PubMed  Google Scholar 

  16. Calapkulu M, Cander S, Gul OO, Ersoy C. Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes Metab Syndr. 2019;13(2):1031–4.

    PubMed  Google Scholar 

  17. Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 Diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42.

    PubMed  PubMed Central  Google Scholar 

  18. Katsuyama H, Hamasaki H, Adachi H, Moriyama S, Kawaguchi A, Sako A, et al. Effects of Sodium-glucose cotransporter 2 inhibitors on metabolic parameters in patients with type 2 Diabetes: a chart-based analysis. J Clin Med Res. 2016;8(3):237–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318(19):1925–6.

    PubMed  Google Scholar 

  20. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? Oxford University Press; 2015. pp. 379–88.

  21. Li Y, Gray A, Xue L, Farb MG, Ayalon N, Andersson C, et al. Metabolomic Profiles, Ideal Cardiovascular Health, and risk of Heart Failure and Atrial Fibrillation: insights from the Framingham Heart Study. J Am Heart Assoc. 2023;12(12):e028022.

    PubMed  PubMed Central  Google Scholar 

  22. Qin X, Zhang Y, Zheng Q. Metabolic inflexibility as a pathogenic basis for Atrial Fibrillation. Int J Mol Sci. 2022;23(15).

  23. Lu C, Liu C, Mei D, Yu M, Bai J, Bao X, et al. Comprehensive metabolomic characterization of atrial fibrillation. Front Cardiovasc Med. 2022;9:911845.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Guan B, Li X, Xue W, Tse G, Waleed KB, Liu Y, et al. Blood lipid profiles and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Clin Lipidol. 2020;14(1):133–42e3.

    PubMed  Google Scholar 

  25. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the reporting of Observational studies in Epidemiology using mendelian randomization: the STROBE-MR Statement. JAMA. 2021;326(16):1614–21.

    PubMed  Google Scholar 

  26. The GTEx. Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318–30.

    Google Scholar 

  27. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300–10.

    PubMed  PubMed Central  Google Scholar 

  28. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109(5):767–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Bakker MK, van Straten T, Chong M, Paré G, Gill D, Ruigrok YM. Anti-epileptic drug target perturbation and intracranial Aneurysm risk: mendelian randomization and colocalization study. Stroke. 2023;54(1):208–16.

    CAS  PubMed  Google Scholar 

  30. Ritchie SC, Surendran P, Karthikeyan S, Lambert SA, Bolton T, Pennells L, et al. Quality control and removal of technical variation of NMR metabolic biomarker data in ~ 120,000 UK Biobank participants. Sci Data. 2023;10(1):64.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv. 2020. 2020.08.10.244293.

  32. Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017;49(6):946–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 Diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54(5):560–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and Diseases. Nat Genet. 2018;50(5):693–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, et al. Improving the visualization, interpretation and analysis of two-sample summary data mendelian randomization via the Radial plot and radial regression. Int J Epidemiol. 2018;47(4):1264–78.

    PubMed  PubMed Central  Google Scholar 

  36. Lin Z, Deng Y, Pan W. Combining the strengths of inverse-variance weighting and Egger regression in mendelian randomization using a mixture of regressions model. PLoS Genet. 2021;17(11):e1009922.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing mendelian randomization investigations. Wellcome Open Res. 2019;4:186.

    PubMed  Google Scholar 

  38. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. Psychol Methods. 2002;7(1):83–104.

    PubMed  PubMed Central  Google Scholar 

  39. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.

    PubMed  PubMed Central  Google Scholar 

  40. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14.

    PubMed  PubMed Central  Google Scholar 

  41. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent developments in mendelian randomization studies. Curr Epidemiol Rep. 2017;4(4):330–45.

    PubMed  PubMed Central  Google Scholar 

  42. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–98.

    PubMed  PubMed Central  Google Scholar 

  43. Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, et al. Canagliflozin and Stroke in type 2 Diabetes Mellitus. Stroke. 2019;50(2):396–404.

    CAS  PubMed  Google Scholar 

  44. Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495–502.

    PubMed  Google Scholar 

  45. Fatima K, Suri A, Rija A, Kalim S, Javaid S, Arif Z et al. The effect of sodium-glucose co-transporter 2 inhibitors on Stroke and atrial fibrillation: a systematic review and meta-analysis. Curr Probl Cardiol. 2022:101582.

  46. Li WJ, Chen XQ, Xu LL, Li YQ, Luo BH. SGLT2 inhibitors and atrial fibrillation in type 2 Diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19(1):130.

    PubMed  PubMed Central  Google Scholar 

  47. Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, et al. Protective effects of Sodium-glucose transporter 2 inhibitors on Atrial Fibrillation and Atrial Flutter: a systematic review and Meta- analysis of Randomized Placebo-controlled trials. Front Endocrinol (Lausanne). 2021;12:619586.

    PubMed  Google Scholar 

  48. Sfairopoulos D, Liu T, Zhang N, Tse G, Bazoukis G, Letsas K, et al. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in Heart Failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2023;28(4):925–36.

    CAS  PubMed  Google Scholar 

  49. Li W, Chen X, Xie X, Xu M, Xu L, Liu P, et al. Comparison of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide receptor agonists for Atrial Fibrillation in type 2 Diabetes Mellitus: systematic review with Network Meta-analysis of Randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(3):281–8.

    CAS  PubMed  Google Scholar 

  50. Zhuo M, D’Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, et al. Association of Sodium-glucose Cotransporter-2 inhibitors with Incident Atrial Fibrillation in older adults with type 2 Diabetes. JAMA Netw Open. 2022;5(10):e2235995.

    PubMed  PubMed Central  Google Scholar 

  51. Hsiao FC, Yen KC, Chao TF, Chen SW, Chan YH, Chu PH. New-Onset Atrial Fibrillation in patients with type 2 Diabetes treated with novel glucose-lowering therapies. J Clin Endocrinol Metab. 2022;107(9):2493–9.

    PubMed  Google Scholar 

  52. Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A New Hope: sodium-glucose Cotransporter-2 inhibition to prevent Atrial Fibrillation. J Cardiovasc Dev Dis. 2022;9(8).

  53. Shetty SS, Krumerman A. Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. Cardiovasc Diabetol. 2022;21(1):119.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Peng X, Li L, Zhang M, Zhao Q, Wu K, Bai R, et al. Sodium-glucose cotransporter 2 inhibitors potentially prevent Atrial Fibrillation by ameliorating Ion Handling and mitochondrial dysfunction. Front Physiol. 2020;11:912.

    PubMed  PubMed Central  Google Scholar 

  55. Piccirillo F, Mastroberardino S, Nusca A, Frau L, Guarino L, Napoli N et al. Novel antidiabetic agents and their effects on lipid Profile: a single shot for several Cardiovascular targets. Int J Mol Sci. 2023;24(12).

  56. Yaribeygi H, Maleki M, Reiner Ž, Jamialahmadi T, Sahebkar A. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in Diabetic Milieu. J Clin Med. 2022;11:21.

    Google Scholar 

  57. Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, et al. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in Diabetes patients with Heart Failure. Sci Rep. 2022;12(1):15449.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, et al. How does empagliflozin improve arterial stiffness in patients with type 2 Diabetes Mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):44.

    PubMed  PubMed Central  Google Scholar 

  59. Osto E, Bonacina F, Pirillo A, Norata GD. Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: from clinical evidence to molecular mechanisms. Pharmacol Res. 2023;188:106667.

    CAS  PubMed  Google Scholar 

  60. Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 Diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):8.

    PubMed  PubMed Central  Google Scholar 

  61. Rau M, Thiele K, Korbinian Hartmann NU, Möllmann J, Wied S, Böhm M, et al. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 Diabetes: data from a randomized, placebo-controlled study. Atherosclerosis. 2021;330:8–13.

    CAS  PubMed  Google Scholar 

  62. Harrison SL, Lane DA, Banach M, Mastej M, Kasperczyk S, Jóźwiak JJ, et al. Lipid levels, atrial fibrillation and the impact of age: results from the LIPIDOGRAM2015 study. Atherosclerosis. 2020;312:16–22.

    CAS  PubMed  Google Scholar 

  63. Ding M, Wennberg A, Gigante B, Walldius G, Hammar N, Modig K. Lipid levels in midlife and risk of atrial fibrillation over 3 decades-experience from the Swedish AMORIS cohort: a cohort study. PLoS Med. 2022;19(8):e1004044.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Yang KC, Dudley SC Jr. Oxidative stress and atrial fibrillation: finding a missing piece to the puzzle. Circulation. 2013;128(16):1724–6.

    PubMed  PubMed Central  Google Scholar 

  65. Welty FK. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis? Curr Cardiol Rep. 2013;15(9):400.

    PubMed  PubMed Central  Google Scholar 

  66. Lind V, Hammar N, Lundman P, Friberg L, Talbäck M, Walldius G, et al. Impaired fasting glucose: a risk factor for atrial fibrillation and Heart Failure. Cardiovasc Diabetol. 2021;20(1):227.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Holmes MV, Richardson TG, Ference BA, Davies NM, Davey Smith G. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nat Rev Cardiol. 2021;18(6):435–53.

    PubMed  Google Scholar 

  68. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample mendelian randomization. Genet Epidemiol. 2016;40(7):597–608.

    PubMed  PubMed Central  Google Scholar 

  69. Julkunen H, Cichońska A, Tiainen M, Koskela H, Nybo K, Mäkelä V, et al. Atlas of plasma NMR biomarkers for health and Disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023;14(1):604.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the participants in all the GWASs used in this study and the investigators who made these GWAS data publicly available.

Funding

This study was supported by Shanghai Municipal Health Commission (2022XD017), Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZDCX20212501), Shanghai Municipal Human Resources and Social Security Bureau (2020074), Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR4006).

Author information

Author notes

  1. Jiang Li and Yuefeng Yu contributed equally to this work.

Authors and Affiliations

  1. Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Jiang Li, Yuefeng Yu, Ying Sun, Bowei Yu, Bin Wang, Yingli Lu & Ningjian Wang

  2. School of Public Health, Zhejiang University, Hangzhou, China

    Xiao Tan

  3. Department of Medical Sciences, Uppsala University, Uppsala, Sweden

    Xiao Tan

Authors
  1. Jiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuefeng Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bowei Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yingli Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ningjian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

N.W. and Y.L. conceived and designed the study. J.L. and Y.Y. performed the statistical analysis and drafted the manuscript. Y.S. and B.Y. participated in data collection. X.T. and B.W. critically revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ningjian Wang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Summary-level GWAS statistics used in this study is publicly available and no specific ethical approval was required.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, J., Yu, Y., Sun, Y. et al. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study. Cardiovasc Diabetol 22, 278 (2023). https://0-doi-org.brum.beds.ac.uk/10.1186/s12933-023-02019-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12933-023-02019-8

Keywords

Cardiovascular Diabetology

ISSN: 1475-2840